Potent and selective reversible inhibitor of monoamine oxidase B (MAOB)
TB5 is a potent and selective reversible inhibitor of monoamine oxidase B (MAOB) with a Ki value of 110 nM. A reversible inhibitor should have an advantage over irreversible inhibitors such as selegiline in limiting side effects. Parallel artificial membrane permeation (PAMPA) assays indicated TB5 should be able to cross the blood–brain barrier. TB5 was found nontoxic to cells.
A series of (2E)-1-(5-bromothiophen-2-yl)-3-(para-substituted phenyl)prop-2-en-1-ones (TB1-TB11) was synthesized and tested for inhibitory activity toward human monoamine oxidase (hMAO). All compounds were found to be competitive, selective, and reversible toward hMAO-B except (2E)-1-(5-bromothiophen-2-yl)-3-(4-nitrophenyl)prop-2-en-1-one (TB7) and (2E)-1-(5-bromothiophen-2-yl)-3-(4-chlorophenyl)prop-2-en-1-one (TB8), which were selective inhibitors
The journal of physical chemistry. B, 121(6), 1186-1203 (2017-01-14)
Selective monoamine oxidase-B (MAO-B) inhibitors are imperative in the treatment of various neurodegenerative disorders. Herein, we describe the pharmacophore generation and atom-based three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of previously reported thiophene-based hMAO-B inhibitors by our research group. The aim
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
